Status:
UNKNOWN
Use of Beta-agonists in Stable Severe Congestive Heart Failure
Lead Sponsor:
Rabin Medical Center
Conditions:
Ischemic Cardiomyopathy
Non-ischemic Cardiomyopathy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.
Eligibility Criteria
Inclusion
- Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with a measured EF \<35%, class III as defined by the NYHA with ICD and who receive optimal pharmacological therapy.
Exclusion
- Heart Failure class I, II, IV
- atrial fibrillation
- any significant valvular disease
- chronic obstructive pulmonary disease who treated with inhaled β2 agonist
- significant kidney disease with eGFR \<30%
- severe uncontrolled electrolyte abnormalities
- prior allergic reaction to Salbutamol
- Pregnancy and nursing women
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01447069
Start Date
October 1 2011
End Date
March 1 2012
Last Update
October 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin medical center
Petah Tikva, Israel, 49100